Angela Luzia Branco Pinto Duarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela Luzia Branco Pinto Duarte has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Andréa Tavares Dantas
Department of Clinical Medicine, Federal University of Pernambuco, Recife, Brazil
10 shared publications - Rafaela Silva Guimarães Gonçalves
Universidade Federal de Pernambuco, Brazil
7 shared publications - Claudia Diniz Lopes Marques
Universidade Federal de Pernambuco – UFPE, Recife, Brasil
6 shared publications - Luiz Alcino Gueiros
Federal University of Pernambuco
6 shared publications - Maira Galdino da Rocha Pitta
Universidade Federal de Pernambuco
6 shared publications - Moacyr Jesus Barreto de Melo Rêgo
Universidade Federal de Pernambuco
5 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Universidade Estadual de Maringa in Journal of Physical Education
- Vol. 1 (37)
Effects of mat Pilates on sleep quality of people living with fibromyalgia: A randomized controlled trial
Fibromyalgia is a rheumatic condition frequently associated with sleep disturbances that impair quality of life. The Pilates method (PM) has been shown to improve pain, physical function, muscle strength, and quality of life in individuals with fibromyalgia; however, evidence regarding its effects on sleep remains limited. This randomized clinical trial evaluated the effects of a 12-week mat Pilates program on sleep quality in adults with fibromyalgia. Participants were allocated to a control group (physical activity guidance) or a Pilates group (mat Pilates twice weekly). Sleep quality was assessed before and after the intervention using the Pittsburgh Sleep Quality Index (PSQI). Between-group comparisons were performed using analysis of covariance adjusted for baseline values, and changes in the prevalence of sleep disturbances (PSQI > 10) were analyzed using the McNemar test. Sixteen participants completed the study (mean age: 51.7 ± 5.67 years; women: n = 13, 81.3%). No significant between-group differences were observed in post-intervention PSQI scores. However, the prevalence of sleep disturbances was significantly reduced in the Pilates group after the intervention. These findings indicate that mat Pilates may reduce sleep disturbances in individuals with fibromyalgia.
- 27 February 2026
- Published by Universidade Estadual de Maringa in Journal of Physical Education
- Vol. 1 (37)
Open AccessEffects of mat Pilates on sleep quality of people living with fibromyalgia: A randomized controlled trial
Fibromyalgia is a rheumatic condition frequently associated with sleep disturbances that impair quality of life. The Pilates method (PM) has been shown to improve pain, physical function, muscle strength, and quality of life in individuals with fibromyalgia; however, evidence regarding its effects on sleep remains limited. This randomized clinical trial evaluated the effects of a 12-week mat Pilates program on sleep quality in adults with fibromyalgia. Participants were allocated to a control group (physical activity guidance) or a Pilates group (mat Pilates twice weekly). Sleep quality was assessed before and after the intervention using the Pittsburgh Sleep Quality Index (PSQI). Between-group comparisons were performed using analysis of covariance adjusted for baseline values, and changes in the prevalence of sleep disturbances (PSQI > 10) were analyzed using the McNemar test. Sixteen participants completed the study (mean age: 51.7 ± 5.67 years; women: n = 13, 81.3%). No significant between-group differences were observed in post-intervention PSQI scores. However, the prevalence of sleep disturbances was significantly reduced in the Pilates group after the intervention. These findings indicate that mat Pilates may reduce sleep disturbances in individuals with fibromyalgia.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 86
Chemokine levels (CXCL8/IL-8, CCL2/MCP-1 and CXCL10/IP-10) after T cell stimulation in PBMC cultures reveals potential functional biomarkers for systemic sclerosis
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by progressive fibrosis, particularly affecting the skin, lungs, and gastrointestinal tract, and is associated with higher morbidity and mortality rates compared to other rheumatic diseases. Due to its clinical heterogeneity, early diagnosis remains challenging, as no specific laboratory test is currently available, and diagnosis relies primarily on clinical manifestations. In this context, the identification of biomarkers for the disease is essential, and cytokines and chemokines stand out as promising candidates because they play central roles in pathophysiology and reflect clinical manifestations. However, studies investigating the potential of these mediators as useful biomarkers for the diagnosis of the disease are still scarce. Thus, this study aimed to investigate the potential of the chemokines IL-8 (CXCL8), MCP-1 (CCL2), and IP-10 (CXCL10) as biomarkers for SSc. Peripheral blood mononuclear cells (PBMCs) from SSc patients (n=20) and healthy controls (n= 10) were stimulated in vitro with anti-CD3/CD28 antibodies to activate T cells. Following stimulation, PBMCs from SSc patients secreted significantly higher levels of IL-8 (p = 0.0006) and MCP-1 (p = 0.0382) compared to healthy controls, whereas IP-10 was more abundantly secreted by cells from healthy controls (p= 0.010). IL-8 (AUC = 0.885, p = 0.0007), CCL-2 (AUC= 0.735, p= 0.038), and IP-10 (AUC = 0.785, p = 0.012) demonstrated strong discriminatory power between SSc patients and controls. The differential expression of the chemokines IL-8, CCL-2, and IP-10 after T cell activation suggests their potential as immunological biomarkers to distinguish patients with systemic sclerosis from healthy individuals, contributing to the development of tools to support the diagnosis of the disease.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 86
Open AccessChemokine levels (CXCL8/IL-8, CCL2/MCP-1 and CXCL10/IP-10) after T cell stimulation in PBMC cultures reveals potential functional biomarkers for systemic sclerosis
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by progressive fibrosis, particularly affecting the skin, lungs, and gastrointestinal tract, and is associated with higher morbidity and mortality rates compared to other rheumatic diseases. Due to its clinical heterogeneity, early diagnosis remains challenging, as no specific laboratory test is currently available, and diagnosis relies primarily on clinical manifestations. In this context, the identification of biomarkers for the disease is essential, and cytokines and chemokines stand out as promising candidates because they play central roles in pathophysiology and reflect clinical manifestations. However, studies investigating the potential of these mediators as useful biomarkers for the diagnosis of the disease are still scarce. Thus, this study aimed to investigate the potential of the chemokines IL-8 (CXCL8), MCP-1 (CCL2), and IP-10 (CXCL10) as biomarkers for SSc. Peripheral blood mononuclear cells (PBMCs) from SSc patients (n=20) and healthy controls (n= 10) were stimulated in vitro with anti-CD3/CD28 antibodies to activate T cells. Following stimulation, PBMCs from SSc patients secreted significantly higher levels of IL-8 (p = 0.0006) and MCP-1 (p = 0.0382) compared to healthy controls, whereas IP-10 was more abundantly secreted by cells from healthy controls (p= 0.010). IL-8 (AUC = 0.885, p = 0.0007), CCL-2 (AUC= 0.735, p= 0.038), and IP-10 (AUC = 0.785, p = 0.012) demonstrated strong discriminatory power between SSc patients and controls. The differential expression of the chemokines IL-8, CCL-2, and IP-10 after T cell activation suggests their potential as immunological biomarkers to distinguish patients with systemic sclerosis from healthy individuals, contributing to the development of tools to support the diagnosis of the disease.
- 3 December 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (1) , 292-302
Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients
Background Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and dysregulation of the immune system. The therapeutic options available for SSc have limited efficacy, and there is a clear need for new pharmacological alternatives. Thiazolidinediones (TZD) are molecules that have therapeutic potential for SSc due to their pharmacological properties. In this study, we aimed to evaluate the immunomodulatory activity of a new TZD analogue (LPSF/CR-35) in peripheral blood mononuclear cells (PBMC) from SSc patients. Materials and methods PBMC response to LPSF/CR-35 (100µM) was examined from SSc patients (n = 19) and healthy control subjects (n = 8) following PBMC stimulation with anti-CD3/CD28. Cytokines (IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, and IL-17 A) and chemokines (CXCL8/IL-8, CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and CXCL10/IP-10) levels were quantified in PBMC culture supernatants by cytometric bead array (CBA). In silico analyses were performed to evaluate the binding affinity of LPSF/CR-35 to peroxisome proliferator-activated receptor gamma (PPARγ). Results LPSF/CR-35 treatment significantly reduced the secretion of IL-17 A (p = 0.02), IL-10 (p = 0.001), IL-4 (p = 0.04), CCL2/MCP-1 (p = 0.003), and CXCL8/IL-8 (p = 0.03), while increasing TNF levels (p = 0.004) in PBMCs from SSc patients. Molecular docking predicted high binding affinity of both E (-9.987 kcal/mol) and Z (-9.992 kcal/mol) isomers of LPSF/CR-35 to PPARγ, supporting a possible PPARγ-dependent mechanism. Conclusions Our results indicate that LPSF/CR-35 modulates key cytokines and chemokines involved in SSc immunopathology, possibly through PPARγ activation. These findings support the potential of LPSF/CR-35 as an immunomodulatory agent in SSc. Further studies are needed to elucidate its effects on fibrosis and confirm its mechanism of action.
- 3 December 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (1) , 292-302
Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients
Background Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and dysregulation of the immune system. The therapeutic options available for SSc have limited efficacy, and there is a clear need for new pharmacological alternatives. Thiazolidinediones (TZD) are molecules that have therapeutic potential for SSc due to their pharmacological properties. In this study, we aimed to evaluate the immunomodulatory activity of a new TZD analogue (LPSF/CR-35) in peripheral blood mononuclear cells (PBMC) from SSc patients. Materials and methods PBMC response to LPSF/CR-35 (100µM) was examined from SSc patients (n = 19) and healthy control subjects (n = 8) following PBMC stimulation with anti-CD3/CD28. Cytokines (IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, and IL-17 A) and chemokines (CXCL8/IL-8, CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and CXCL10/IP-10) levels were quantified in PBMC culture supernatants by cytometric bead array (CBA). In silico analyses were performed to evaluate the binding affinity of LPSF/CR-35 to peroxisome proliferator-activated receptor gamma (PPARγ). Results LPSF/CR-35 treatment significantly reduced the secretion of IL-17 A (p = 0.02), IL-10 (p = 0.001), IL-4 (p = 0.04), CCL2/MCP-1 (p = 0.003), and CXCL8/IL-8 (p = 0.03), while increasing TNF levels (p = 0.004) in PBMCs from SSc patients. Molecular docking predicted high binding affinity of both E (-9.987 kcal/mol) and Z (-9.992 kcal/mol) isomers of LPSF/CR-35 to PPARγ, supporting a possible PPARγ-dependent mechanism. Conclusions Our results indicate that LPSF/CR-35 modulates key cytokines and chemokines involved in SSc immunopathology, possibly through PPARγ activation. These findings support the potential of LPSF/CR-35 as an immunomodulatory agent in SSc. Further studies are needed to elucidate its effects on fibrosis and confirm its mechanism of action.
- Open Access
- 14 October 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (10) , e70635
TIMP‐2 as a Potential Indicator of Persistent Arthralgia in Chikungunya: Evidence From a Brazilian Cohort Study
Chikungunya virus (CHIKV) infection can trigger a sustained inflammatory response, often leading to chronic musculoskeletal pain. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the persistence of arthralgia through their involvement in joint tissue remodeling and degradation. This study aimed to evaluate the potential of MMPs and TIMPs as plasma biomarkers of persistent arthralgia in individuals diagnosed with Chikungunya Fever (CHIKF). A prospective cohort study was conducted using plasma samples from 133 CHIKF‐positive individuals recruited during the acute or post‐acute phases. Sociodemographic and clinical data were collected at outpatient visits. At 90 days post‐symptom onset, participants were assessed for persistent arthralgia using a self‐reported Visual Analog Scale (VAS) for joint pain and categorized into two groups: Recovered (VAS 0–3, n = 71) or Persistent Arthralgia (VAS 4–10, n = 62). Plasma levels of MMP‐2, MMP‐9, and TIMP‐2 were quantified using multiplex bead‐based ELISA (LegendPlex), while MMP‐1, MMP‐3, MMP‐14/MT1‐MMP, and TIMP‐1 were measured via sandwich ELISA. Plasma samples from 51 CHIKV‐negative individuals were used as controls. Statistical analyzes were performed using GraphPad Prism v9.0, IBM SPSS Statistics and Stata. Among post‐acute participants, lower MMP‐2 levels were significantly associated with recovery compared to those with persistent arthralgia and to controls. TIMP‐2 levels varied significantly across clinical outcomes, supporting its involvement in CHIKV‐induced pathology. Multivariate analysis identified swollen joints, skin rash, and elevated TIMP‐2 levels during the post‐acute phase as independent predictors of persistent arthralgia in the chronic phase. No significant differences were observed for MMP‐1, MMP‐3, MMP‐9, MMP‐14, or TIMP‐1. These findings suggest a potential role for TIMP‐2 and musculoskeletal manifestations as early indicators of chronic joint symptoms following CHIKV infection. Further studies are needed to validate these biomarkers and better understand the mechanisms underlying chronic Chikungunya‐related arthralgia across diverse populations.
- 14 October 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (10) , e70635
Open AccessTIMP‐2 as a Potential Indicator of Persistent Arthralgia in Chikungunya: Evidence From a Brazilian Cohort Study
Chikungunya virus (CHIKV) infection can trigger a sustained inflammatory response, often leading to chronic musculoskeletal pain. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the persistence of arthralgia through their involvement in joint tissue remodeling and degradation. This study aimed to evaluate the potential of MMPs and TIMPs as plasma biomarkers of persistent arthralgia in individuals diagnosed with Chikungunya Fever (CHIKF). A prospective cohort study was conducted using plasma samples from 133 CHIKF‐positive individuals recruited during the acute or post‐acute phases. Sociodemographic and clinical data were collected at outpatient visits. At 90 days post‐symptom onset, participants were assessed for persistent arthralgia using a self‐reported Visual Analog Scale (VAS) for joint pain and categorized into two groups: Recovered (VAS 0–3, n = 71) or Persistent Arthralgia (VAS 4–10, n = 62). Plasma levels of MMP‐2, MMP‐9, and TIMP‐2 were quantified using multiplex bead‐based ELISA (LegendPlex), while MMP‐1, MMP‐3, MMP‐14/MT1‐MMP, and TIMP‐1 were measured via sandwich ELISA. Plasma samples from 51 CHIKV‐negative individuals were used as controls. Statistical analyzes were performed using GraphPad Prism v9.0, IBM SPSS Statistics and Stata. Among post‐acute participants, lower MMP‐2 levels were significantly associated with recovery compared to those with persistent arthralgia and to controls. TIMP‐2 levels varied significantly across clinical outcomes, supporting its involvement in CHIKV‐induced pathology. Multivariate analysis identified swollen joints, skin rash, and elevated TIMP‐2 levels during the post‐acute phase as independent predictors of persistent arthralgia in the chronic phase. No significant differences were observed for MMP‐1, MMP‐3, MMP‐9, MMP‐14, or TIMP‐1. These findings suggest a potential role for TIMP‐2 and musculoskeletal manifestations as early indicators of chronic joint symptoms following CHIKV infection. Further studies are needed to validate these biomarkers and better understand the mechanisms underlying chronic Chikungunya‐related arthralgia across diverse populations.
- 22 June 2025
- Published by Wiley in Oral Diseases
- Vol. 31 (12) , 3506-3507
Oral Health‐Related Quality of Life and Sicca Syndrome in Survivors of Severe COVID‐19
- 22 June 2025
- Published by Wiley in Oral Diseases
- Vol. 31 (12) , 3506-3507
Oral Health‐Related Quality of Life and Sicca Syndrome in Survivors of Severe COVID‐19
- Open Access
- 19 March 2025
- Published by Associacao Internacional Uniao das Americas in Revista Pleiade
- Vol. 19 (46) , 27-41
Efeitos do tratamento manipulativo osteopático nas manifestações musculoesqueléticas da fase crônica da febre Chikungunya: ensaio clínico randomizado
Contexto: A febre Chikungunya (FC) é caracterizada clinicamente por manifestações crônicas articulares que levam a incapacidade funcional. O Tratamento Manipulativo Osteopático (TMO) incorpora estratégias terapêuticas utilizadas para tratar a dor e perda da capacidade funcional através de manipulações manuais. Objetivo: O objetivo desse estudo foi verificar os efeitos do TMO nos membros superiores de pacientes que apresentam dor e rigidez crônica pós FC. Métodos: Trata-se de um ensaio clínico randomizado, realizado no Ambulatório de Reumatologia do Hospital das Clínicas de Pernambuco, com 44 pacientes, alocados aleatoriamente e divididos em dois grupos, grupo osteopatia (GO) com n=24 e grupo controle (GC) com n=20. Os instrumentos avaliativos utilizados foram, a EVA, Algometria, Brief Pain Inventory Questionnaire (BPI), Disabilities of the Arm (DASH), Nine hole peg test (9HTP). Resultados: Após 4 semanas, os pacientes do GO apresentaram redução da intensidade da dor no BPI e EVA (p<0,005), além de pontuações mais baixas do BPI interferência da dor (p<0,005) e pontuações mais baixas no DASH (p<0,005) em comparação com o grupo controle. Os resultados da algometria não foram estatisticamente significativos, apesar de apresentarem maior resistência a dor a pressão, e mantidos durante o período de follow up. Neste estudo, os pacientes que realizaram o TMO por 4 semanas apresentaram melhora da dor e da capacidade funcional com a manutenção dessa resposta após 30 dias.
- 19 March 2025
- Published by Associacao Internacional Uniao das Americas in Revista Pleiade
- Vol. 19 (46) , 27-41
Open AccessEfeitos do tratamento manipulativo osteopático nas manifestações musculoesqueléticas da fase crônica da febre Chikungunya: ensaio clínico randomizado
Contexto: A febre Chikungunya (FC) é caracterizada clinicamente por manifestações crônicas articulares que levam a incapacidade funcional. O Tratamento Manipulativo Osteopático (TMO) incorpora estratégias terapêuticas utilizadas para tratar a dor e perda da capacidade funcional através de manipulações manuais. Objetivo: O objetivo desse estudo foi verificar os efeitos do TMO nos membros superiores de pacientes que apresentam dor e rigidez crônica pós FC. Métodos: Trata-se de um ensaio clínico randomizado, realizado no Ambulatório de Reumatologia do Hospital das Clínicas de Pernambuco, com 44 pacientes, alocados aleatoriamente e divididos em dois grupos, grupo osteopatia (GO) com n=24 e grupo controle (GC) com n=20. Os instrumentos avaliativos utilizados foram, a EVA, Algometria, Brief Pain Inventory Questionnaire (BPI), Disabilities of the Arm (DASH), Nine hole peg test (9HTP). Resultados: Após 4 semanas, os pacientes do GO apresentaram redução da intensidade da dor no BPI e EVA (p<0,005), além de pontuações mais baixas do BPI interferência da dor (p<0,005) e pontuações mais baixas no DASH (p<0,005) em comparação com o grupo controle. Os resultados da algometria não foram estatisticamente significativos, apesar de apresentarem maior resistência a dor a pressão, e mantidos durante o período de follow up. Neste estudo, os pacientes que realizaram o TMO por 4 semanas apresentaram melhora da dor e da capacidade funcional com a manutenção dessa resposta após 30 dias.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (4) , e20231254
Quality of sleep in individuals with systemic sclerosis and its correlation with functional disability and quality of life: a cross-sectional study
This study aimed to evaluate the quality of sleep in individuals with systemic sclerosis and its correlation with the quality of life and disability.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (4) , e20231254
Open AccessQuality of sleep in individuals with systemic sclerosis and its correlation with functional disability and quality of life: a cross-sectional study
This study aimed to evaluate the quality of sleep in individuals with systemic sclerosis and its correlation with the quality of life and disability.
- 28 November 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (1) , 289-295
Ultrasound assessment of diaphragm and quadriceps muscles and its relationship with handgrip and respiratory muscle strength in patients with systemic sclerosis: a cross-sectional study
Background Muscle dysfunction may cause disability and reduce the quality of life of patients with systemic sclerosis (SSc) when compared to healthy individuals. However, the literature on the topic is scarce and uses several criteria for assessing muscle dysfunction in this population. Objectives To compare diaphragm and quadriceps muscle thickness, diaphragm mobility, and handgrip strength between patients with SSc and healthy individuals. Method This cross-sectional study included 16 patients with SSc and 16 self-reported healthy individuals matched for age. We assessed quadriceps and diaphragm thickness and diaphragmatic mobility (ultrasound), handgrip strength (hand-held dynamometer), and respiratory muscle strength (manovacuometer). Patients also responded to the Health Assessment Questionnaire Disability Index and the International Physical Activity Questionnaire. Results Patients with SSc presented lower quadriceps thickness (p < 0.0001), diaphragmatic mobility (p = 0.01), handgrip (p < 0.0001), and respiratory muscle strength (p < 0.0001) than healthy individuals. A moderate positive correlation was observed between handgrip strength and quadriceps thickness in patients with SSc (rho = 0.576; p = 0.02). Conclusions Patients with SSc presented reduced quadriceps thickness, diaphragmatic mobility, handgrip, and respiratory muscle strength when compared to healthy individuals Also, handgrip strength was correlated with quadriceps thickness in patients with SSc, suggesting that loss of muscle mass accompanies loss of peripheral muscle strength group of patients. Key Points • SSc patients presented reduced quadriceps thickness and diaphragmatic mobility • SSc patients have reduced handgrip and respiratory muscle strength • Lower handgrip muscle strength correlated with lower quadriceps thickness.
- 28 November 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (1) , 289-295
Ultrasound assessment of diaphragm and quadriceps muscles and its relationship with handgrip and respiratory muscle strength in patients with systemic sclerosis: a cross-sectional study
Background Muscle dysfunction may cause disability and reduce the quality of life of patients with systemic sclerosis (SSc) when compared to healthy individuals. However, the literature on the topic is scarce and uses several criteria for assessing muscle dysfunction in this population. Objectives To compare diaphragm and quadriceps muscle thickness, diaphragm mobility, and handgrip strength between patients with SSc and healthy individuals. Method This cross-sectional study included 16 patients with SSc and 16 self-reported healthy individuals matched for age. We assessed quadriceps and diaphragm thickness and diaphragmatic mobility (ultrasound), handgrip strength (hand-held dynamometer), and respiratory muscle strength (manovacuometer). Patients also responded to the Health Assessment Questionnaire Disability Index and the International Physical Activity Questionnaire. Results Patients with SSc presented lower quadriceps thickness (p < 0.0001), diaphragmatic mobility (p = 0.01), handgrip (p < 0.0001), and respiratory muscle strength (p < 0.0001) than healthy individuals. A moderate positive correlation was observed between handgrip strength and quadriceps thickness in patients with SSc (rho = 0.576; p = 0.02). Conclusions Patients with SSc presented reduced quadriceps thickness, diaphragmatic mobility, handgrip, and respiratory muscle strength when compared to healthy individuals Also, handgrip strength was correlated with quadriceps thickness in patients with SSc, suggesting that loss of muscle mass accompanies loss of peripheral muscle strength group of patients. Key Points • SSc patients presented reduced quadriceps thickness and diaphragmatic mobility • SSc patients have reduced handgrip and respiratory muscle strength • Lower handgrip muscle strength correlated with lower quadriceps thickness.
- 13 January 2023
- Published by Wiley in Oral Diseases
- Vol. 29 (7) , 2592-2599
Association between axial spondyloarthritis and temporomandibular disorders: A systematic review
This study aimed to assess the frequency of temporomandibular disorders (TMDs) in patients with axial spondyloarthritis (axSpA) compared with the healthy individuals. We systematically searched PubMed, Embase, Scopus, Web of Science, CINAHL, and Google Scholar databases from their inception until 2022, without language restriction. A standardized dataset was used to extract data from the observational studies. Patients were required to have axial spondyloarthritis and clinical and/or radiographic evidence of temporomandibular joint dysfunction. Meta-analysis was performed with a random effects model. A systematic review was registered under number CRD42020206283. We identified seven relevant studies, which provided data for 745 patients and 216 temporomandibular disorders events. The combined odds ratio (OR) showed that the risk of temporomandibular disorders in individuals with axial spondyloarthritis was higher than the control group (pooled OR = 5.26, 95% CI 2.50-11, 06; p < 0.02; I-2 = 58%). Also, these individuals do not appear to refer possible temporomandibular joint symptoms to the rheumatologist or dentist. The results of this systematic review and meta-analysis suggest that patients with axial spondyloarthritis have an increased frequency of temporomandibular disorders. TMDs seem to be secondary to postural alterations rather than direct involvement of the temporomandibular joints (TMJs).
- 13 January 2023
- Published by Wiley in Oral Diseases
- Vol. 29 (7) , 2592-2599
Association between axial spondyloarthritis and temporomandibular disorders: A systematic review
This study aimed to assess the frequency of temporomandibular disorders (TMDs) in patients with axial spondyloarthritis (axSpA) compared with the healthy individuals. We systematically searched PubMed, Embase, Scopus, Web of Science, CINAHL, and Google Scholar databases from their inception until 2022, without language restriction. A standardized dataset was used to extract data from the observational studies. Patients were required to have axial spondyloarthritis and clinical and/or radiographic evidence of temporomandibular joint dysfunction. Meta-analysis was performed with a random effects model. A systematic review was registered under number CRD42020206283. We identified seven relevant studies, which provided data for 745 patients and 216 temporomandibular disorders events. The combined odds ratio (OR) showed that the risk of temporomandibular disorders in individuals with axial spondyloarthritis was higher than the control group (pooled OR = 5.26, 95% CI 2.50-11, 06; p < 0.02; I-2 = 58%). Also, these individuals do not appear to refer possible temporomandibular joint symptoms to the rheumatologist or dentist. The results of this systematic review and meta-analysis suggest that patients with axial spondyloarthritis have an increased frequency of temporomandibular disorders. TMDs seem to be secondary to postural alterations rather than direct involvement of the temporomandibular joints (TMJs).
- Open Access
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 28
Headache in patients with systemic lupus erythematosus: a pilot study
Introduction Headache is a symptom frequently reported by patients with Systemic Lupus Erythematosus (SLE), but it remains controversial as to whether the prevalence is higher than in the those without the disease and if there is an association with disease activity. Objectives 1) to compare the prevalence, monthly frequency and impact of headaches between patients with SLE and a control group without the disease and 2) to compare the prevalence, monthly frequency and impact of headaches between patients with active SLE and those without disease activity Methods This is a case-control study. The case group consisted of patients diagnosed with SLE in regular follow-up at the Rheumatology outpatient clinic of the Hospital das Clínicas, UFPE, excluding those with a previous diagnosis of secondary headache or overlapping autoimmune diseases. A control group, matched for sex and age, consisted of hospital staff and friends and relatives of patients who had no previous diagnosis of secondary headache or autoimmune disease. Data on SLE and headache were collected through interviews and questionnaires administered by a neurologist. Headache impact was assessed using the Headache Impact Test (HIT-6) scale, anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS) and disease activity was evaluated using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K modified scale, considering clinical and laboratory data from the last 30 days. All participants who reported at least one headache attack in the last year were considered as having headache and specific diagnoses were made based on the 3rd edition of the International Classification of Headache Disorders. SLE patients with SLEDAI-2K ≥ 6 were considered as having disease activity. Statistical analyzes were performed in SPSS 28.0 with significance defined as p < 0.05.... (To see the complet abstract, please, check out the PDF.)
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 28
Open AccessHeadache in patients with systemic lupus erythematosus: a pilot study
Introduction Headache is a symptom frequently reported by patients with Systemic Lupus Erythematosus (SLE), but it remains controversial as to whether the prevalence is higher than in the those without the disease and if there is an association with disease activity. Objectives 1) to compare the prevalence, monthly frequency and impact of headaches between patients with SLE and a control group without the disease and 2) to compare the prevalence, monthly frequency and impact of headaches between patients with active SLE and those without disease activity Methods This is a case-control study. The case group consisted of patients diagnosed with SLE in regular follow-up at the Rheumatology outpatient clinic of the Hospital das Clínicas, UFPE, excluding those with a previous diagnosis of secondary headache or overlapping autoimmune diseases. A control group, matched for sex and age, consisted of hospital staff and friends and relatives of patients who had no previous diagnosis of secondary headache or autoimmune disease. Data on SLE and headache were collected through interviews and questionnaires administered by a neurologist. Headache impact was assessed using the Headache Impact Test (HIT-6) scale, anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS) and disease activity was evaluated using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K modified scale, considering clinical and laboratory data from the last 30 days. All participants who reported at least one headache attack in the last year were considered as having headache and specific diagnoses were made based on the 3rd edition of the International Classification of Headache Disorders. SLE patients with SLEDAI-2K ≥ 6 were considered as having disease activity. Statistical analyzes were performed in SPSS 28.0 with significance defined as p < 0.05.... (To see the complet abstract, please, check out the PDF.)